MYC and Miyoshi myopathy: siRNAs silence oncogenic transcripts in MM through RNA interference, demonstrating promise against targets such as BCL2 family [202], MYC (NCT02110563, DCR-MYC, Dicerna Pharmaceuticals, Inc. [203], terminated in a phase Ib/II trial), IRF4 [204], CXCL13 [77]—all involved in MM proliferation, survival, and bone marrow retention.